Healthcare Medical Devices Biotechnology

AI in Drug Discovery Market Report Cover

AI in Drug Discovery Market

AI in Drug Discovery Market Report Cover

AI in Drug Discovery Market Size, Share, Growth & Industry Analysis, By Component (Software, Services.), By Computational Method (Machine Learning, Deep Learning, Bioinformatics, Cheminformatics, Natural Language Processing.), By Therapeutic Area (Oncology, Infectious Diseases, Cardiology, Endocrinology, Neurology, Psychology, Other.) and Regional Analysis, 2023-2030

Author : Omkar R.

Pages : 120

Base Year : 2022

Release : February 2024

Report ID: KR404

AI in Drug Discovery Market Size

The global AI in Drug Discovery Market size was valued at USD 4.07 billion in 2022 and is projected to reach USD 36.06 billion by 2030, growing at a CAGR of 31.94% from 2023 to 2030. In the scope of work, the report includes solutions offered by companies such as Bayer AG, Novartis International AG, Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Takeda Pharmaceutical Company Limited, Hoffmann-La Roche Ltd, Johnson & Johnson, Sanofi S.A., Merck & Co., Inc. and Others.

The global market for AI in drug discovery is experiencing significant growth due to the increasing demand for novel drugs. This growth is driving a transformation in the pharmaceutical industry, with companies and researchers utilizing artificial intelligence to speed up the discovery of innovative medications. The rise in complex diseases and the need for more effective and personalized treatments have led pharmaceutical and biotechnology companies to look for innovative solutions. AI technologies provide advanced data analysis, predictive modeling, and fast candidate screening, which reduce the time and cost of drug discovery. As a result, there are substantial investments, collaborations, and advancements in the market, with AI playing a leading role in finding new therapeutics for global health challenges.

Analyst’s Review 

The AI in drug discovery market is experiencing significant trends that are shaping the future of the industry. The adoption of AI in this sector has been rapidly increasing. This highlights the growing importance of AI in the industry. AI is no longer just a peripheral tool but a crucial component in the drug discovery process. The development of advanced machine learning and deep learning models has greatly enhanced the accuracy and efficiency of selecting drug candidates, resulting in a remarkable 30% reduction in drug development timelines.

Collaborations between large pharmaceutical companies and innovative startups are on the rise, promoting innovation and the exchange of AI technologies. Additionally, the integration of AI for repurposing existing drugs and the potential for personalized medicine are driving market growth. This indicates a future in which AI is likely to play an indispensable role in bringing life-saving drugs to market faster and more cost-effectively.

Market Definition

Artificial Intelligence (AI) is a powerful technology that mimics human intelligence in machines, enabling them to perform tasks that typically require human thinking. In the field of drug discovery, AI has brought about a revolution, transforming the pharmaceutical industry. It is used for data analysis, identifying patterns, and making predictions. AI utilizes machine learning algorithms, deep learning neural networks, bioinformatics, and cheminformatics to speed up different stages of the drug development process.

While AI holds great potential, regulatory agencies such as the FDA and the EMA have established strict guidelines to ensure the safety and effectiveness of AI-driven drug candidates. These guidelines require thorough validation and transparent documentation of AI algorithms, including reliable data sources and clear model interpretation. Regulatory agencies aim to strike a balance between innovation and patient safety.

The regulatory landscape is evolving to accommodate the unique characteristics of AI. For instance, the FDA has introduced the Software Precertification (Pre-Cert) Program, which aims to streamline the regulatory process for AI-based medical devices. However, ensuring the transparency, accountability, and reliability of AI models remains a major challenge. Drug discovery companies must invest in regulatory compliance, data security, and comprehensive documentation as they navigate this emerging field. The dynamic regulatory environment underscores the importance of aligning AI advancements with regulatory oversight to maximize the benefits of AI in drug discovery while upholding stringent safety and quality standards.

AI in Drug Discovery Market Dynamics

The key factor driving the growth of the AI in drug discovery market is the ability of the technology to enhance drug candidate screening and lead optimization. AI technology empowers pharmaceutical and biotech companies to significantly improve their screening and optimization processes for potential drug candidates. By utilizing advanced algorithms and predictive models, AI can quickly analyze large datasets and identify the most promising compounds with greater accuracy and efficiency. This speeds up the drug development process and reduces costs. Through streamlined lead optimization, AI enables the identification of drug candidates that have a higher likelihood of success. This drives innovation and allows life-saving treatments to reach patients faster and at a lower cost compared to traditional methods.

One of the major restraints in the AI-driven drug discovery market is the lack of high-quality labeled data for training AI models. While artificial intelligence is excellent at recognizing patterns and making predictions, its effectiveness heavily relies on having access to robust and well-annotated datasets. In the pharmaceutical industry, obtaining large, diverse, and accurately labeled datasets can be extremely difficult, especially for rare diseases and complex biological processes. Without comprehensive data, AI models may struggle to provide accurate insights, limiting their ability to identify potential drug candidates and optimize leads effectively.

A lucrative growth opportunity for the AI-driven drug discovery market is the advancement of personalized medicine and targeted therapies. AI can analyze large datasets, including patient genetics, to customize treatments based on individual characteristics. This approach promises more effective interventions with fewer side effects, thereby optimizing outcomes and minimizing harm. By identifying specific genetic markers, AI can predict how patients will respond to different drugs, enabling the development of precision medicine and targeted therapies. The potential to revolutionize healthcare by providing treatments tailored to each patient's genetic makeup highlights the transformative power of AI in shaping the future of medicine and ultimately enhancing patient care.

Data privacy and security present significant challenges in the AI-driven drug discovery market. As the industry relies heavily on extensive datasets, there is a risk of sensitive patient information and proprietary data being compromised. Protecting this data is crucial to safeguard patient privacy and maintain the integrity of research. Compliance with data protection laws is essential to prevent legal and ethical issues that can arise from data breaches. Implementing strong encryption, access controls, and cybersecurity measures is vital to address these challenges and build trust in AI applications.

Segmentation Analysis

The global AI in drug discovery market is segmented based on component, computational method, therapeutic area, end users, and geography.

By Component

Based on the component, the market is bifurcated into software and services. The software segment led the market in 2022, reaching an impressive revenue of USD 2.58 billion. This robust growth can be attributed to the vital role software solutions play in driving AI applications in the drug discovery process. Pharmaceutical companies and research organizations rely heavily on advanced software tools for tasks such as data analysis, molecular modeling, and AI-driven data processing. These software solutions improve efficiency and accuracy, ultimately speeding up the drug discovery process. As a result, the software segment has become the primary revenue contributor in the market.

By Computational Method

Based on computational method, the market is divided into machine learning, deep learning, bioinformatics, cheminformatics, and natural language processing. In 2022, the machine learning segment garnered the highest revenue share due to the versatility and effectiveness of the technology in drug discovery. Machine learning algorithms excel in data analysis, predictive modeling, and pattern recognition, making them essential in identifying promising drug candidates. This has resulted in the segment achieving a dominant position in the market.

By Therapeutic Area

Based on therapeutic area, the market is divided into oncology, infectious diseases, cardiology, endocrinology, neurology, psychology, and others. The psychology segment is estimated to experience significant growth over the forecast period, with a projected CAGR of 43.48%. This surge is mainly fueled by the growing emphasis on mental health and the rising need for more efficient treatment options. AI's ability to analyze intricate behavioral and psychological data aligns with the evolving needs of the healthcare industry, presenting substantial opportunities for AI applications in psychology. As a result, the segment is expected to exhibit the highest growth rate in the market through the projected timeline.

AI in Drug Discovery Market Regional Analysis

Based on region, the global AI in drug discovery market is classified into North America, Europe, Asia Pacific, MEA, and Latin America.

AI in Drug Discovery Market Size & Share, By Region, 2024-2031

The North America AI in Drug Discovery Market share stood around 43.00% in 2022 in the global market, with a valuation of USD 1.75 billion. The region boasts a strong pharmaceutical industry and is a hub for technological innovation, fostering extensive collaborations for research and development between pharmaceutical giants and AI startups. Furthermore, favorable government regulations and a robust healthcare infrastructure have played a crucial role in fueling regional market growth. Additionally, North America's ample access to high-quality labeled data and advanced research institutions provided a competitive advantage. These factors, along with a proactive approach to AI adoption in drug discovery, have solidified North America's leading position in the market.

Asia Pacific is set to experience rapid growth in the foreseeable future, with a projected CAGR of 41.59% between 2023 and 2030. The region is witnessing a significant increase in pharmaceutical research and development activities, as well as a growing emphasis on integrating AI technology. The expansion of healthcare infrastructure, a large population of patients, and increased investment in AI-driven drug discovery initiatives are key factors driving the growth of the domestic market. Additionally, the emergence of Asia Pacific as a global player in AI and biotechnology is facilitating significant advancements in these fields, thereby bolstering its potential for high growth.

Competitive Landscape

The global AI in drug discovery market report will provide valuable insight with an emphasis on the fragmented nature of the industry. Prominent players are focusing on several key business strategies such as partnerships, mergers and acquisitions, product innovations, and joint ventures to expand their product portfolio and increase their market shares across different regions. Expansion and investments are the major strategic initiatives adopted by companies in the sector. Industry players are investing extensively in R&D activities, building new manufacturing facilities, and supply chain optimization.

List of Key Companies in AI in Drug Discovery Market

Key Industry Developments 

  • September 2023 (Partnership): Merck announced two strategic drug discovery collaborations with UK-based companies BenevolentAI and Exscientia. The partnerships aimed to utilize artificial intelligence (AI) for advancing research in oncology, neurology, and immunology. The integration of AI in R&D processes accelerated drug development, aligning with Merck's strategy to enhance productivity and pipeline output sustainably.
  • May 2023 (Partnership): Eli Lilly partnered with XtalPi, a pharmaceutical AI firm, to enhance drug discovery by using artificial intelligence and computational tools. The collaboration aimed to optimize formulations, develop more efficient drug delivery systems, and accelerate drug development, benefiting patients worldwide through innovative pharmaceutical solutions.

The Global AI in Drug Discovery Market is Segmented as:

By Component

  • Software
  • Services

By Computational Method

  • Machine Learning
  • Deep Learning
  • Bioinformatics
  • Cheminformatics
  • Natural Language Processing

By Therapeutic Area

  • Oncology
  • Infectious Diseases
  • Cardiology
  • Endocrinology
  • Neurology
  • Psychology
  • Other

By End Users

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • U.K.
    • Spain
    • Germany
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific
  • The Middle East & Africa
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America.
  • Check Icon Additional Company Profiles
  • Check Icon Additional Countries
  • Check Icon Cross Segment Analysis
  • Check Icon Regional Market Dynamics
  • Check Icon Country-Level Trend Analysis
  • Check Icon Competitive Landscape Customization
  • Check Icon Extended Forecast Years
  • Check Icon Historical Data Up to 5 Years
Frequently Asked Questions (FAQ's)
The global market is projected to reach USD 36.06 billion by 2030, growing at a CAGR of 31.94% from 2023 to 2030.
The global market was valued at USD 4.07 billion in 2022.
Rising demand for personalized medicine and increasing investment in AI-powered drug discovery are driving the pharmaceutical industry's transformation.
Top manufacturers of AI in drug discovery are Bayer AG, Novartis International AG, Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Sanofi S.A., Merck & Co., Inc., and others.
Asia-Pacific is the fastest growing region with the CAGR of 41.59% in the forecasted period (2023-2030) with the market value forecasted to reach at USD 13.97 billion.
By component, software segment will hold the maximum share in the AI in drug discovery market with the revenue value of USD 21.36 billion in 2030.
Get the latest!

Get actionable strategies to empower your business and market domination

  • Deliver Revenue Impact
  • Demand Supply Patterns
  • Market Estimation
  • Real-Time Insights
  • Market Intelligence
  • Lucrative Growth Opportunities
  • Micro & Macro Economic Factors
  • Futuristic Market Solutions
  • Revenue-Driven Results
  • Innovative Thought Leadership